SCHEMBL2799647

SCHEMBL2799647

O=C(O)N1C(=O)N(C(=O)O)C2(CC(OCc3ccccc3)C2)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.38
CTSL P07711 2/20 0.38
CTSB P07858 2/20 0.38
CTSK P43235 2/20 0.38
AGTR2 P50052 2/20 0.36
BCHE P06276 2/20 0.36
OPRM1 P35372 2/20 0.35
OPRL1 P41146 2/20 0.35
DPP4 P27487 1/20 0.35
CTSV O60911 1/20 0.35
CTSS P25774 1/20 0.35
CTSC P53634 1/20 0.35
CTSF Q9UBX1 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
ALDH1A1 P00352 2/20 0.35
FKBP1A P62942 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2A Q12879 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802050 0.91 SMN1; SMN2 (0.40) EPHX2BCHEALDH1A1FKBP1A
SCHEMBL2800251 0.87 KLK7 (0.38) EPHX2
SCHEMBL12081860 0.84 CTRB1 (0.43) BCHEALDH1A1FKBP1A
SCHEMBL12081753 0.84 CTRB1 (0.43) BCHEALDH1A1FKBP1A
SCHEMBL2802047 0.84 CTRB1 (0.43) BCHEALDH1A1FKBP1A
SCHEMBL12082089 0.81 KLK7 (0.38) BCHEALDH1A1
SCHEMBL2800249 0.81 KLK7 (0.38) BCHEALDH1A1
SCHEMBL12081802 0.81 KLK7 (0.38) BCHEALDH1A1
SCHEMBL2640274 0.70 EPHX2 (0.47) EPHX2CTSLCTSBCTSKAGTR2
SCHEMBL31471348 0.69 EPHX2 (0.46) EPHX2CTSLCTSBCTSKAGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172459-B1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME TOKUYAMA CORP (JP) 2014-03-19 EP disclosed
US-8404860-B2 Compound having hydantoin ring and method of producing the same TOKUYAMA CORPORATION (JP) 2013-03-26 US disclosed
US-20120289705-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME SHIIGI HIROFUMI (JP) 2012-11-15 US disclosed
US-8258313-B2 Compound having hydantoin ring and method of producing the same TOKUYAMA CORPORATION (JP) 2012-09-04 US disclosed
US-20100184993-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME TOKUYAMA CORPORATION (JP) 2010-07-22 US disclosed
EP-2172459-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME Tokuyama Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289705-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME CASP14, CYP8B1, DDT EPHX2 547/4885CTSL 1178/4885CTSB 1487/4885
US-20100184993-A1 COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME CASP14, CYP8B1, DDT EPHX2 547/4885CTSL 1178/4885CTSB 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.